Andere Sprachen Scilex Holding Company

Aktien

A3DW1Z

US80880W1062

SCLX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.05.2024			% 5 Tage	% 1. Jan.
0,87 ^USD	+6,32 %		+4,79 %	-57,35 %

14.05.	Scilex Holding teilt mit, dass das Bundesgericht den Vergleich mit Takeda Pharmaceutical im Patentstreit um Gloperba genehmigt hat	MT
14.05.	Scilex Holding erklärt, dass das Bundesgericht den Vergleich mit Takeda Pharmaceutical im Patentstreit um Gloperba genehmigt hat	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14.05.
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14.05.
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®	14.05.
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock	13.05.
Scilex Holding Company Announces $15 Million Registered Direct Offering	24.04.
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for Gross and Net Sales for ZTlido for the First Quarter 2024	17.04.
Scilex Issues Preliminary Q1 Sales Results for ZTlido	16.04.
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses	16.04.
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group	10.04.
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool	09.04.
Scilex : Submission of Matters to a Vote of Security Holders - Form 8-K	05.04.
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend	27.03.
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients	21.03.
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	20.03.
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	20.03.
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed	20.03.
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed	20.03.
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®	20.03.
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation	19.03.
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Scilex Holding Company

Aktien

A3DW1Z

US80880W1062

SCLX

Andere Sprachen

Filter